Search
forLearn
5 / 801 resultslearn multipeptides
learn Biotinyl-GHK
learn Meta-bisulfite
learn hairgenyl
Research
5 / 315 results research Low Heterozygosity and Historical Bottleneck Effect Depicted From the Genome Assembly of the Indus River Dolphin (Platanista minor )
The Indus River dolphin has low genetic diversity due to a past bottleneck and human impact.
research Increased frequency of heterozygoshy for the 21 hydroxylase deficiency among hersute females
Women with excessive hair growth or polycystic ovary disease may more often carry a gene variant for 21 hydroxylase deficiency.
research Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess
Some women with PCOS have CYP21 mutations and IRS1 variants, but these genetic factors are not major contributors to PCOS.
research The Phenotypic and Genotypic Spectra of Ichthyosis With Confetti Plus Novel Genetic Variation in the 3′ End ofKRT10
Ichthyosis with confetti is a genetic skin disorder with consistent ectodermal malformations and various KRT10 gene mutations.
research Homologous recombination induced by doxazosin mesylate and saw palmetto in the Drosophila wing‐spot test
Doxazosin mesylate and saw palmetto cause genetic changes in fruit flies.
Community Join
5 / 1000+ resultscommunity Finasteride and male phenotypes
community Genetic variations associated with response to Dutasteride. Why is it never mentioned?
Genetic variations influence how people respond to dutasteride for hair loss, with some benefiting more from finasteride. Dutasteride is effective for most, but genetic differences may cause it to be less effective for some.
community RU58481, are side effects exegerated?
community KX-826 Phase II Results Just Dropped (Male AGA) – Key Takeaways
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
community Hope Medicine announces HMI-115 phase II clinical trial for androgenetic alopecia in China
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.